Your browser doesn't support javascript.
loading
m6A RNA Methylation Regulators Impact Prognosis and Tumor Microenvironment in Renal Papillary Cell Carcinoma.
Chen, Lianze; Hu, Baohui; Song, Xinyue; Wang, Lin; Ju, Mingyi; Li, Zinan; Zhou, Chenyi; Zhang, Ming; Wei, Qian; Guan, Qiutong; Jiang, Longyang; Chen, Ting; Wei, Minjie; Zhao, Lin.
Affiliation
  • Chen L; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China.
  • Hu B; Liaoning Key Laboratory of Molecular Targeted Anti-Tumor Drug Development and Evaluation, Liaoning Cancer Immune Peptide Drug Engineering Technology Research Center, Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, China Medical University, Sheny
  • Song X; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China.
  • Wang L; Liaoning Key Laboratory of Molecular Targeted Anti-Tumor Drug Development and Evaluation, Liaoning Cancer Immune Peptide Drug Engineering Technology Research Center, Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, China Medical University, Sheny
  • Ju M; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China.
  • Li Z; Liaoning Key Laboratory of Molecular Targeted Anti-Tumor Drug Development and Evaluation, Liaoning Cancer Immune Peptide Drug Engineering Technology Research Center, Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, China Medical University, Sheny
  • Zhou C; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China.
  • Zhang M; Liaoning Key Laboratory of Molecular Targeted Anti-Tumor Drug Development and Evaluation, Liaoning Cancer Immune Peptide Drug Engineering Technology Research Center, Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, China Medical University, Sheny
  • Wei Q; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China.
  • Guan Q; Liaoning Key Laboratory of Molecular Targeted Anti-Tumor Drug Development and Evaluation, Liaoning Cancer Immune Peptide Drug Engineering Technology Research Center, Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, China Medical University, Sheny
  • Jiang L; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China.
  • Chen T; Liaoning Key Laboratory of Molecular Targeted Anti-Tumor Drug Development and Evaluation, Liaoning Cancer Immune Peptide Drug Engineering Technology Research Center, Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, China Medical University, Sheny
  • Wei M; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China.
  • Zhao L; Liaoning Key Laboratory of Molecular Targeted Anti-Tumor Drug Development and Evaluation, Liaoning Cancer Immune Peptide Drug Engineering Technology Research Center, Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, China Medical University, Sheny
Front Oncol ; 11: 598017, 2021.
Article de En | MEDLINE | ID: mdl-33796449
Mots clés
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Type d'étude: Guideline / Prognostic_studies Langue: En Journal: Front Oncol Année: 2021 Type de document: Article Pays d'affiliation: Chine
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Type d'étude: Guideline / Prognostic_studies Langue: En Journal: Front Oncol Année: 2021 Type de document: Article Pays d'affiliation: Chine